Novel insights on use of doxorubicin to treat chemoresistant TNBC by Immunotherapy
<p>Doxorubicin, a WHO listed essential medicine, is used primarily as a combination of taxane/ anthracycline (doxorubicin)/cyclophosphamide (TAC), for treating malignant diseases including triple-negative breast cancer (TNBC). TNBC is a subtype of breast cancer categorized by deficient estroge...
में बचाया:
| मुख्य लेखकों: | , |
|---|---|
| स्वरूप: | पुस्तक |
| प्रकाशित: |
International Journal of Immunotherapy and Cancer Research - Peertechz Publications,
2020-07-18.
|
| विषय: | |
| ऑनलाइन पहुंच: | Connect to this object online. |
| टैग: |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | peertech__10_17352_2455-8591_000024 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Tze-Chen Hsieh |e author |
| 700 | 1 | 0 | |a Joseph M Wu |e author |
| 245 | 0 | 0 | |a Novel insights on use of doxorubicin to treat chemoresistant TNBC by Immunotherapy |
| 260 | |b International Journal of Immunotherapy and Cancer Research - Peertechz Publications, |c 2020-07-18. | ||
| 520 | |a <p>Doxorubicin, a WHO listed essential medicine, is used primarily as a combination of taxane/ anthracycline (doxorubicin)/cyclophosphamide (TAC), for treating malignant diseases including triple-negative breast cancer (TNBC). TNBC is a subtype of breast cancer categorized by deficient estrogen receptor, progesterone receptor, and epidermal growth factor receptor HER-2 [1]. TNBC is challenging to treat due to its genotype and phenotype heterogeneity [2-5], aggressiveness, recurrence [6-10], and resistance to existing therapies. Roughly, 25-45% TNBC patients receiving TAC as preoperative therapy achieve complete response and excellent long-term prognosis [11], while patients who fail TAC have poor prognosis and few therapeutic choices [2].</p> | ||
| 540 | |a Copyright © Tze-Chen Hsieh et al. | ||
| 546 | |a en | ||
| 655 | 7 | |a Mini Review |2 local | |
| 856 | 4 | 1 | |u https://doi.org/10.17352/2455-8591.000024 |z Connect to this object online. |